EA200600973A1 - ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 - Google Patents

ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2

Info

Publication number
EA200600973A1
EA200600973A1 EA200600973A EA200600973A EA200600973A1 EA 200600973 A1 EA200600973 A1 EA 200600973A1 EA 200600973 A EA200600973 A EA 200600973A EA 200600973 A EA200600973 A EA 200600973A EA 200600973 A1 EA200600973 A1 EA 200600973A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diamins
pde
pyrido
pyrimidin
inhibitors
Prior art date
Application number
EA200600973A
Other languages
English (en)
Other versions
EA010424B1 (ru
Inventor
Томас Артур Бейер
Роберт Джеймс Чамберс
Келвин Лэм
Мей ЛИ
Эндрю Ян Моррелл
Дэвид Дьюэйн Томпсон
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200600973A1 publication Critical patent/EA200600973A1/ru
Publication of EA010424B1 publication Critical patent/EA010424B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы (I), их пролекарствам и фармацевтически приемлемым солям соединений или пролекарств, где значение символов n, Х и Y определено в настоящей заявке, а также к фармацевтическим композициям, комбинациям и применениям упомянутых соединений.
EA200600973A 2003-12-16 2004-12-06 ПИРИДО[2,3-d]ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 EA010424B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52999403P 2003-12-16 2003-12-16
PCT/IB2004/004013 WO2005061497A1 (en) 2003-12-16 2004-12-06 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors

Publications (2)

Publication Number Publication Date
EA200600973A1 true EA200600973A1 (ru) 2006-10-27
EA010424B1 EA010424B1 (ru) 2008-08-29

Family

ID=34710150

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600973A EA010424B1 (ru) 2003-12-16 2004-12-06 ПИРИДО[2,3-d]ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2

Country Status (39)

Country Link
US (1) US20070135457A1 (ru)
EP (1) EP1697356B1 (ru)
JP (1) JP4073944B2 (ru)
KR (1) KR100816179B1 (ru)
CN (1) CN100439366C (ru)
AP (1) AP2006003632A0 (ru)
AR (1) AR046766A1 (ru)
AT (1) ATE387446T1 (ru)
AU (1) AU2004303609A1 (ru)
BR (1) BRPI0417663A (ru)
CA (1) CA2549510A1 (ru)
CL (1) CL2008001920A1 (ru)
DE (1) DE602004012154T2 (ru)
DK (1) DK1697356T3 (ru)
EA (1) EA010424B1 (ru)
EC (1) ECSP066643A (ru)
ES (1) ES2299888T3 (ru)
GE (1) GEP20094720B (ru)
GT (1) GT200400268A (ru)
HN (1) HN2004000538A (ru)
HR (1) HRP20080142T3 (ru)
IL (1) IL175813A0 (ru)
IS (1) IS8474A (ru)
MA (1) MA28270A1 (ru)
MX (1) MXPA06006777A (ru)
NL (1) NL1027787C2 (ru)
NO (1) NO20063231L (ru)
PE (1) PE20050681A1 (ru)
PL (1) PL1697356T3 (ru)
PT (1) PT1697356E (ru)
RS (1) RS50575B (ru)
SI (1) SI1697356T1 (ru)
SV (1) SV2005001979A (ru)
TN (1) TNSN06186A1 (ru)
TW (1) TWI291961B (ru)
UA (1) UA83091C2 (ru)
UY (1) UY28671A1 (ru)
WO (1) WO2005061497A1 (ru)
ZA (1) ZA200604970B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960372B1 (en) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
KR20090098783A (ko) * 2006-09-21 2009-09-17 토시키 오구로 경조직 재생 촉진제
JP5472638B2 (ja) * 2008-03-18 2014-04-16 日産化学工業株式会社 １−（置換フェニル）−１−置換シリルエーテル、アルコールまたはケトンの製造方法および中間体
US20120065165A1 (en) * 2008-10-31 2012-03-15 Arginetix, Inc Compositions and methods of treating endothelial disorders
EP2456440B1 (en) 2009-07-22 2015-08-19 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
EA201391558A1 (ru) 2011-04-20 2014-05-30 Глэксо Груп Лимитед Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
GEP20166554B (en) 2012-04-25 2016-10-10 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
EP3018123B1 (en) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amide compound
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
JPWO2015012328A1 (ja) * 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3087060B1 (en) 2013-12-23 2020-05-13 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
RU2712165C2 (ru) * 2014-08-01 2020-01-24 Фирмениш Са Твердая дисперсия амидных пищевых ароматизаторов
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JP2021504466A (ja) 2017-11-23 2021-02-15 オスロ ウニヴェルシティ ホスピタル ホーエフ 頻脈の治療
CN109758458B (zh) * 2019-03-05 2021-02-23 中国人民解放军陆军军医大学第二附属医院 抑制Crif1与PKA相互作用的化合物的应用
US11648254B2 (en) 2021-03-02 2023-05-16 Kumquat Biosciences Inc. Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling
US11912708B2 (en) 2022-04-20 2024-02-27 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US2926166A (en) * 1954-01-04 1960-02-23 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
US3021332A (en) * 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
US2924599A (en) * 1956-07-16 1960-02-09 Anchor Chemical Company Ltd Derivatives of 1:3:5-triazanaphthalene
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
US3288792A (en) * 1962-07-05 1966-11-29 Burroughs Wellcome Co Method of preparing 2, 4-diamino-6-alkylpyrido (2, 3-d) pyrimidines
DE3422824A1 (de) * 1984-06-20 1986-01-02 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue herbizid wirksame sulfonylharnstoffe
US6194166B1 (en) * 1993-05-24 2001-02-27 Takara Shuzo Co., Ltd. Gene regulating aureobasidin sensitivity
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4

Also Published As

Publication number Publication date
IS8474A (is) 2006-05-18
DK1697356T3 (da) 2009-01-12
EA010424B1 (ru) 2008-08-29
CN1894245A (zh) 2007-01-10
EP1697356B1 (en) 2008-02-27
GEP20094720B (en) 2009-06-25
ECSP066643A (es) 2006-10-25
PL1697356T3 (pl) 2008-07-31
SI1697356T1 (sl) 2008-06-30
TNSN06186A1 (fr) 2007-11-15
ZA200604970B (en) 2007-11-28
RS50575B (sr) 2010-05-07
MXPA06006777A (es) 2006-08-23
CN100439366C (zh) 2008-12-03
AR046766A1 (es) 2005-12-21
MA28270A1 (fr) 2006-11-01
ATE387446T1 (de) 2008-03-15
PE20050681A1 (es) 2005-10-04
NO20063231L (no) 2006-07-11
HN2004000538A (es) 2008-02-21
CL2008001920A1 (es) 2008-10-17
JP2007513996A (ja) 2007-05-31
HRP20080142T3 (en) 2008-06-30
TWI291961B (en) 2008-01-01
IL175813A0 (en) 2006-10-05
AP2006003632A0 (en) 2006-06-30
TW200522952A (en) 2005-07-16
WO2005061497A1 (en) 2005-07-07
UA83091C2 (en) 2008-06-10
EP1697356A1 (en) 2006-09-06
BRPI0417663A (pt) 2007-04-03
NL1027787A1 (nl) 2005-06-21
SV2005001979A (es) 2005-12-13
UY28671A1 (es) 2005-07-29
ES2299888T3 (es) 2008-06-01
CA2549510A1 (en) 2005-07-07
PT1697356E (pt) 2008-05-05
KR20060105776A (ko) 2006-10-11
US20070135457A1 (en) 2007-06-14
NL1027787C2 (nl) 2006-03-09
KR100816179B1 (ko) 2008-03-28
JP4073944B2 (ja) 2008-04-09
DE602004012154D1 (de) 2008-04-10
GT200400268A (es) 2005-09-20
AU2004303609A1 (en) 2005-07-07
DE602004012154T2 (de) 2009-03-12

Similar Documents

Publication Publication Date Title
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
ATE437872T1 (de) Proteinkinaseinhibitoren
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
MXPA03005464A (es) Agentes antivirales.
EA200601125A1 (ru) 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы
EA200601100A1 (ru) 6-замещённые 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
TNSN03110A1 (en) Azaindoles.
GB0114286D0 (en) Nucleoside Derivatives
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
EA200700144A1 (ru) Производные пиридопиримидина, их получение, их применение в терапии
EA200700099A1 (ru) Производные пиридина
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
WO2007146124A3 (en) Deuterated tadalafil derivatives
PT828728E (pt) Di-hidrobenzofuranos de fenilo
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU